Ignite Creation Date:
2025-12-24 @ 1:31 PM
Ignite Modification Date:
2026-02-26 @ 2:14 AM
Study NCT ID:
NCT01473095
Status:
COMPLETED
Last Update Posted:
2017-10-23
First Post:
2011-11-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | AKT | View |
| None | ARQ 092 | View |
| None | Targeted therapy | View |
| None | Molecular therapy | View |
| None | Biomarker | View |
| None | Phase 1 | View |
| None | Phase I | View |
| None | Endometrial cancer | View |
| None | Lymphoma | View |
| None | AKT pathway | View |
| None | AKT signaling | View |
| None | AKT inhibitor | View |
| None | AKT pan inhibitor | View |
| None | AKT1 | View |
| None | AKT2 | View |
| None | AKT3 | View |
| None | AKT1 mutation | View |
| None | AKT1-E17K | View |
| None | AKT1-E17K mutation | View |
| None | AKT 2 inhibitor | View |
| None | AKT 3 inhibitor | View |
| None | AKT 3 amplification | View |
| None | PI3K AKT mTOR signalling pathway | View |
| None | mTOR inhibitor | View |
| None | PI3K inhibitor | View |
| None | Clinical oncology | View |
| None | Tumor | View |
| None | Tumour | View |
| None | PIK3CA H1047R mutation | View |